On June 16, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the first bispecific antibody-receptor recombinant protein targeting human CD47 x HER2 (IMM2902), authorized by the United States Patent Office (APPLICATION No.: US 16/535,075). As the most important pharmaceutical markets in the world, the United States took the lead in approving the patent authorization of IMM2902, which will greatly improve the market competitiveness of the product. The patent authorization and approval of the IMM2902 project in China, Japan, the European Union and other countries/regions is also in progress.

IMM2902 is a CD47 x HER2 bispecific antibody in the world's most cutting-edge research field for solid tumors. The project was previously approved by the China National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) to conduct clinical trials on June 29 and August 21, 2021, respectively. The new drug candidate targeting CD47 has entered the clinical research stage. On February 15, 2022, IMM2902 completed the first subject enrollment and dosing, and the clinical trial is progressing smoothly. The IMM2902 project was authorized by the US Patent Office is another major milestone for the company!

Dr. Tian, Wenzhi, the founder, chairman and CEO of ImmuneOnco, said:

 "I am very pleased to see that our IMM2902 project invention patent has been authorized by the US Patent Office. The IMM2902 is designed based on our mAb-Trap technology platform. It is a bi-specific molecule targeting CD47 and HER2. The molecule is developed through the high affinity activity of HER2 to enable the drug to preferentially bind to tumor cells, so that at the same time it has the characteristics of not binding to human erythrocytes and avoiding the "antigen sink effect", thus greatly enhancing the specific synergistic effect of the dual targets against tumors. IMM2902 will have great value of clinical and commercial potentials."